Another observational study was released supporting the idea that a medburning medication helps clinical outcomes in coronavirus patients.
Famotidine, which is used to treat heartburn and is often sold as Pepcid AC, has been associated with improved clinical outcomes in COVID-19 patients, according to a recent study from Hartford Hospital that is accepted in the American Journal of Gastroenterology.
“The main finding of our single-center, retrospective study of hospital COVID-19 patients is that use of famotidine is associated with improved clinical outcome, including lower hospital mortality and a lower overall endpoint of death and / or intubation,” author of the study, Jeffrey F. Mather, of the Division of Research Administration at Hartford Hospital, said in one report.
Researchers have developed a database for all COVID-19 patients and their clinical information to answer questions about the medical outcomes in their coronavirus treatment. The database allowed researchers to observe the effect of experiments on patients with other conditions and the effect of medications on the course of the disease, Rocco Orlando, head of academic affairs at Hartford Healthcare, told Fox News.
Famotidine in Pepcid, an acid-reducing drug used in hospitals patients with COVID-19 were associated with a lower risk of death, a lower risk of combined outcome of death and intubation, and lower levels of adverse effects in the blood of hospitalized patients with COVID-19, he said.
NHALED DRUG shows promise in treating CORONAVIRUS: STUDY
Famotidine, a co-burn for heartburn, has been linked to improved clinical outcomes in COVID-19 patients, according to a recent study from Hartford Hospital. (iStock)
The research team discovered that treating patients with famotidine was associated with certain markers that are potential signs of severe forms of the virus, according to health experts.
According to research reports, another analysis found that famotidine worked well in coronavirus patients who had the highest national warning score, a measure that health care professionals use to determine the disease severity of a patient intervention and critical care treatment , states health experts. It is still being investigated how this drug affects SARS-Cov-2, the scientific name for the new coronavirus that causes COVID-19, according to reports.
BLOOD TEST IDENTIFICATIONS WHEN CORONAVIRUS PATIENTS CAN BE HELPED OR DISTURBED BY STEROID TREATMENT
“There have been a few small observational studies and retrospective reviews that increase the potential benefit of Pepcid in early COVID disease.” Dr. Ira Schmelkin, head of the gastroenterology division at Baystate Health in Springfield, Mass., Told Fox News. “Doctors in China noticed early on that older patients with lower socioeconomic status seemed to be dying at a lower rate. It was noted that these patients took the cheaper famotidine than the more expensive Proton pump inhibitors, “Schmelkin told Fox News.
The next step in the study would be a randomized placebo-controlled prospective study to see if famotidine is clinically beneficial, said the head of gastroenterology.
The Hartford researchers said in reports that their findings should be interpreted with caution because it is a retrospective, observational, single-center study. Like Schmelkin, they suggested that further research is needed into the use and dosage of famotidine in the treatment of new coronavirus.
